COMUNICADO: Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Ery

Actualizado 20/07/2009 8:03:32 CET

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has completed delivery of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to FDA's approval of the Company's Biologics License Application for ABthrax. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

GlaxoSmithKline Forward-Looking Statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in GSK's Annual Report on Form 20-F for 2008.

HGS: Media :Jerry Parrott, Vice President, Corporate Communications, +1-301-315-2777, Investors: Peter Vozzo, Senior Director, Investor Relations, +1-301-251-6003; GSK: U.K. Media Inquiries: Philip Thomson, +44-020-8047-5502, David Outhwaite, +44-020-8947-5502, Stephen Rea, +44-020-8047-5502, U.S. Media Inquiries: Holly Russell, +1-919-483-2839, Kevin Colgan, +1-919-483-2839; European Analyst/Investor Inquiries, David Mawdsley, +44-020-8047-5564, Sally Ferguson, +44-020-8047-5543, Gary Davies, +44-020-8047-5503; U.S. Analyst/Investor Inquiries: Tom Curry, +1-215-751-5419, Jen Hill Baxter, +1-215-751-7002 / Logo:

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación